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Cerebral metabolism in major depressive
disorder: a voxel-based meta-analysis of positron
emission tomography studies
Liang Su1,2*†, Yiyun Cai1,3†, Yifeng Xu3, Anirban Dutt2, Shenxun Shi1,3 and Elvira Bramon2,4*
Abstract
Background: Major depressive disorder (MDD) is a common mental illness with high lifetime prevalence close to
20%. Positron emission tomography (PET) studies have reported decreased prefrontal, insular and limbic cerebral
glucose metabolism in depressed patients compared with healthy controls. However, the literature has not always
been consistent. To evaluate current evidence from PET studies, we conducted a voxel-based meta-analysis of cerebral
metabolism in MDD.
Method: Data were collected from databases including PubMed and Web of Science, with the last report up to April
2013. Voxel-based meta-analyses were performed using the revised activation likelihood estimation (ALE) software.
Results: Ten whole-brain-based FDG-PET studies in MDD were included in the meta-analysis, comprising 188 MDD
patients and 169 healthy controls. ALE analyses showed the brain metabolism in bilateral insula, left lentiform nucleus
putamen and extra-nuclear, right caudate and cingulate gyrus were significantly decreased. However, the brain activity
in right thalamus pulvinar and declive of posterior lobe, left culmen of vermis in anterior lobe were significantly
increased in MDD patients.
Conclusion: Our meta-analysis demonstrates the specific brain regions where possible dysfunctions are more
consistently reported in MDD patients. Altered metabolism in insula, limbic system, basal ganglia, thalamus, and
cerebellum and thus these regions are likely to play a key role in the pathophysiology of depression.
Keywords: Major depressive disorder, Positron emission tomography, Meta-analysis, Activation likelihood estimation
Background
The application of neuroimaging techniques, such as
Positron Emission Tomography (PET), to the study of
major depressive disorder can contribute to the develop-
ment of pathophysiologic models and to the understand-
ing of the neurobiology of the disease [1]. Both fMRI
and PET enable creation of functional connectivity maps
of distinct spatial distributions of brain regions. How-
ever, fMRI and PET measure changes in the composition
of blood and brain metabolism, respectively. Only PET
allows the measurement of cerebral glucose metabolism
in vivo [2].
Some PET studies typically showed that depressed sub-
jects have reduced lateral prefrontal metabolism and
increased medial prefrontal and subgenual cingulate me-
tabolism [3,4]. Also some studies reported lower regional
glucose metabolism in mood disorders in dorsolateral,
ventral subgenual and doromedial prefrontal cortical
regions. Our team found that, compared with healthy
controls, depression patients demonstrated decreased
regional cerebral glucose metabolism rate in bilateral
caudate, superior temporal gyrus, inferior frontal gyrus,
middle frontal gyrus, right lingual gyrus and left cingulate
gyrus, superior temporal gyrus [4]. However, these studies
had inconsistent results, the other studies also found
that MDD patients showed greater glucose uptake in
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ventrolateral prefrontal cortical and paralimbic regions
compared to healthy subjects [5-7].
In a previous meta-analysis of neuroimaging studies
using PET, Single Photon Emission Computed Tomog-
raphy (SPECT) and functional Magnetic Resonance Im-
aging (fMRI) in major depression, Fitzgerald et al [8]
reported that the dorsal cingulate gyrus, middle and
dorsolateral prefrontal cortex, insula and superior tem-
poral gyrus are hypoactive at rest and show a lack of ac-
tivation during negative mood states that improves with
SSRI treatment. According to Delaveau et al [9] antide-
pressants increase the activation of dorsolateral, dor-
somedial and ventrolateral prefrontal cortices in one
PET study and eight fMRI studies; whereas another
meta-analysis of six MRI and four PET studies by Sacher
et al [10] claims that the activation of the amygdala,
hippocampus, parahippocampal region, ventral anterior
cingulate cortex, orbitofrontal cortex, and insula is de-
creased. These meta-analyses have dealt with literature
from a variety of functional neuroimaging technologies
and this may have contributed to the apparent inconsist-
ent findings.
Meta-analyses are essential for summarizing the litera-
ture, comparing results in a standardized fashion, and
quantifying the relationship between study characteris-
tics and findings [10]. However, it is difficult to compare
and combine data across studies using different imaging
methods such as PET and fMRI [11]. We perform the
new ALE meta-analysis which widened of samples by in-
cluding Chinese studies. Thus the present meta-analysis
will focus only on a more homogeneous literature of
studies comparing cerebral glucose metabolism mea-
sured with PET in patients with major depressive dis-
order and controls.
Methods
Literature search and inclusion criteria
According to PRISMA (Preferred Reporting Items for Sys-
tematic reviews and Meta-Analyses) guidelines [12],
search strategy and selection criteria Data were identified
by electronic searches of PubMed (January 1978 to April
2013), the Chinese ‘MEDLINE’ China Biological Medicine
Database [13] (CBM-disc 1979 to April 2013), China
National Knowledge Infrastructure (CNKI 1996 to April
2013), Cochrane Library and Web of Science (1978 to
April 2013), with the terms “Depressive”, “Depression”,
“PET”, “positron emission tomography”, “FDG” and “18 F-
Fluorodeoxyglucose”. References related to the identified
articles were hand searched as reported in our previous
study [14]. We only included studies comparing major de-
pression patients and control subjects.
All studies had to meet the following criteria: (1) peer-
reviewed original research articles, (2) MDD diagnosis ac-
cording to internationally recognized diagnostic criteria,
(3) reported age matched control group, (4) measured glu-
cose metabolism (PET), and (5) results reported as coordi-
nates in a normalized standard stereotactic space [Talairach
or Montreal Neurological Institute (MNI) reference sys-
tem], (6), at least five subjects in each of the patient and
healthy comparison groups [15]. Studies had to be available
in English or Chinese, and involve adult participants.
Studies reporting only results pre- and post-anti
depressive treatment without healthy control group, or
reporting post-medication effects only were excluded.
Studies using region of interest (ROI) method were ex-
cluded [5] because they did not report brain coordinate
and we only included studies using a voxel-by-voxel image
analysis method. The literature search, selection of studies
according to the inclusion and exclusion criteria, and
compilation of coordinates for the contrasts were per-
formed independently by two investigators.
Meta-analysis methods
Meta-analyses were performed using the revised activation
likelihood estimation (ALE) software implemented in
GingerALE 2.0 http://www.brainmap.org/ale/ [16-20]. An
improved version of this method was published by Eickh-
off et al [16]. The input coordinates were weighted to
form estimates of activation likelihood for each intracere-
bral voxel. The activation likelihood of each voxel in
standard space was then combined to form a statistic map
of the ALE score at each voxel. We calculated ALE maps
separately for FDG-PET studies.
Voxel-by-voxel analyses may increase the likelihood of
reporting false positive results, since they require tens or
hundreds of thousands of statistical comparisons. This
was addressed by correcting P values for the number of
independent resolution elements within a search area and
by constraining the size of the search area [21]. The result-
ing ALE map was threshold at p <0.05 (corrected for mul-
tiple comparisons by false discovery rate (FDR), and a
minimum cluster size of supra threshold voxels exceeding
100 mm3 was imposed. ALE results were overlaid onto an
optimized individual anatomical T1-template http://www.
brainmap.org/ale/Colin27_T1_seg_MNI_2x2x2.nii.gz [22].
Primary literature
There were 126 studies initially identified. After limiting
the results by the criteria described above, 10 whole-
brain-based FDG-PET studies in MDD were considered
eligible to enter the meta-analysis. These included a total
of 188 patients and 169 healthy controls as showed in
Figure 1. Compared MDD patients and control samples,
all of the 10 PET studies reported decreased brain activ-
ity, but only 8 studies reported increased metabolism
changes in patients. The average sample size per study
was 18.8 ± 9.4 patients and 16.9 ± 8.92 controls. The gen-
der ratio of the patient samples was approximately even
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(54.1% females). More detailed information on included
studies can be found in Table 1.
Results
Summarize the studies included comparison of MDD and
normal controls
Summarize the studies included along with the total
number of activation foci observed, ALE analyses were
separately carried out ten increased 10 studies (54 foci)
and eight decreased studies (41 foci) brain metabolism
in MDD patients.
Decreased metabolism in MDD
As illustrated in Figure 2 and Table 2, we found signifi-
cant decreases in cluster size within the cortico-limbic
circuit, a network relevant to MDD, including both in-
sula (BA 13, right and insula, cluster size: 536 and
152 mm3, with a maximum ALE value of 0.0111 and
0.0103, respectively), left extra-nuclear (BA 13, cluster-
size; 312 mm3, with a maximum ALE value of 0.0113),
right caudate head (cluster-size; 176 mm3, with a max-
imum ALE value of 0.009), left lentiform nucleus puta-
men (cluster-size; 152 mm3, with a maximum ALE value
of 0.0103) and right cingulate gyrus (BA 31; cluster size:
152 mm3, maximum ALE value of 0.0103).
Figure 1 Flow Diagram of voxel-based meta-analysis of PET
studies in MDD.
Table 1 Details of the 10 primary studies included in this meta-analysis
Year Author Disorder Patients Controls Depression PET
Software
And
Medication
Sample
Size
Gender Mean Age
(SD)
Sample
Size
Gender Mean Age
(SD)
Severity HDRS) FWHM
2001 Saxena [23] MDD 27 13 M, 14 F 38.2(11.1) 17 8 M,
9 F
32.5(11.7) 17 20.8(5.0) SPM 96, 16 mm *
2001 Brody [24] MDD 24 11 M, 13 F 38.9(11.4) 16 8 M,
8 F
35.6(18.3) 17, 19.4(5.5) SPM 96, 10 mm **
2001 Kennedy [25] MDD 13 13 M 36(10) 24 24 M 31.7(6.7) 17 22.4(3.6) SPM 96, 8 mm treated with
antidepressants
2002 Kimbrell [7] MDD 37 13 M, 24 F 43.4(13.0) 37 13 M,
24 F
43.4(12.5) 28, 16.9(8.3) SPM 95, 10 mm medication-free
2003 Kegeles [26] MDD 19 6 M,
13 F
16(11) 10 4 M, 6 F 39(19) 17, 22.3(3.9) SPM 96, 8 mm medication-free
at least 14 days
2005 Zhang [27] MDD 14 4 M,
10 F
43.8(9.3) 11 3 M, 8 F 43.0(7.8) 17, 27.8(6.2) SPM 2b, 8 mm treated with
antidepressants
2006 Su [4] MDD 6 2 M,
4 F
71(6) 10 4 M, 6 F 67.6(2.9) 24, 39.7(3.2) SPM 2, 10 mm first episode and
medication-free
2007 Aihara [28] MDD 24 9 M,
15 F
52.4(13.4) 23 8 M, 15 F 54.8(12.6) 21, 32.0 ± 6.8 SPM 99, 10 mm medication-free
2009 Smith [29] MDD 16 6 M,
10 F
65.3(9.1) 13 5 M, 8 F 67.4(7.4) 24, 26.0(3.5) SPM 99, 8 mm medication-free
2009 Wu [30] MDD 8 5 M,
3 F
47.1(9.3) 8 5 M, 3 F 45.1(8.2) 17, 23.1(3.9) SPM 2b, 8 mm medication-free
Note: FWHM = Full Width at Half Maximum, SPM = Statistical Parametric Mapping, M =man, F = female, HDRS = Hamilton Depression Rating Scale.
*Either treatment naïve or off medication for more than 1 year.
**Either treatment naïve or off medication at least 2 weeks.
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Increased metabolism in MDD
As illustrated in Figure 2 which was produced by Mango
Image Viewer (http://www.brainmap.org/tools.html) we
found significant increases in cluster size relevant to
MDD, including the right thalamus pulvinar (cluster
size: 304 mm3, with a maximum ALE value of 0.0123),
left culmen of vermis in the anterior lobe cortex (clus-
ter-size: 296 mm3, maximum ALE value of 0.0119), and
right declive of the posterior lobe (cluster size: 264 mm3,
with a maximum ALE value of 0.0106). The peak coordi-
nates are shown in the Table 2.
Discussion
This meta-analysis was undertaken to test current theor-
etical models of MDD that propose abnormal ventral
frontal, basal ganglia and limbic activity on FDG-PET
studies. Our main results are that patients with MDD
have decreased brain metabolism in bilateral insula, right
cingulate gyrus and caudate and left putamen and extra-
nuclear. In the meta-analysis we also found increased
glucose metabolism in right thalamus and posterior lobe
declive, and left culmen of vermis in MDD patients. The
results showed that in MDD patients the cluster size of re-
duced glucose metabolism was higher than the cluster size
of increased glucose metabolism. Our results showed that
depression patients had a dysfunction regions including
hypoactive metabolism in insula and limbic system with
compensatory increased activity in thalamus.
The meta-analysis results demonstrated that MDD pa-
tients exhibit decreased brain activation on bilateral insula,
particularly in the right insula. Using fMRI Wiebking et al
[31] found that MDD patients showed reduced neural ac-
tivity during rest periods, particularly in the bilateral anter-
ior insula. Delavearu et al, in a previous meta-analysis also
found decreased insula activation in MDD patients [9].
Using [15O-H2O] positron emission tomography, Savitz
et al. [32] also found that the left posterior insula is a
relevant region in MDD. These results, using different neu-
roimaging methods, consistently show that the insula plays
an important role in the neuropathology of depression.
The results also verify that the limbic system including
cingulate gyrus and the basal ganglia including caudate
head, lentiform nucleus putamen and extra-nuclear had
abnormal brain metabolism in MDD patients. Results
from a previous study indicated that in the context of
untreated symptoms of depression these regions showed
decreased activation and that limbic right posterior
cingulate and right basal ganglia activation were seen
after anti depression treatment [33]. Our meta-analysis
showed the limbic lobe and basal ganglia decreases are a
similar to those reported by Lai et al. [34] and Tol et al.
[35]. The results suggest that the limbic system and
basal ganglia might be the targets of treatment, and that
antidepressants may exert their benefits by means of in-
creasing brain metabolism in these regions [36].
The second interesting result from our analysis is that
certain regions are increased in MDD patients. Some
Figure 2 3D (right) and 2D (left) ALE map representing the
decreased metabolism (color in green) of insula, limbic system
and basal ganglia, and the increased metabolism of thalamus,
and cerebellum (color in red) in MDD patients compared to
normal controls (P<0.05, FDR-corrected) (produced by Mango
Image Viewer, http://www.brainmap.org/tools.html).
Table 2 Results from ALE-analysis of PET studies in MDD patients (P < 0.05 corrected for multiple comparisons by false
discovery rate)
Hemisphere BA volume (m3) x y z Peak ALE value
A. Areas of decreased glucose metabolism in MDD patients
Insula R 13 536 36 22 0 0.01111734
Extra-Nuclear L 13 312 -44 8 -14 0.01131126
Caudate Head R 176 12 20 -6 0.00999559
Insula L 13 152 -40 -6 0 0.01027422
Lentiform Nucleus. Putamen L 152 -32 -16 8 0.01027356
Limbic Lobe. Cingulate Gyrus R 31 152 12 -26 40 0.01027141
B. Areas of increased glucose metabolism in MDD patients
Thalamus. Pulvinar R 304 16 -24 4 0.01226161
Cerebellum Anterior Lobe. Culmen of Vermis L 296 0 -66 -6 0.01194303
Cerebellum Posterior Lobe. Declive R 264 20 -58 -12 0.01064389
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studies showed that MDD patients had higher brain ac-
tivity in thalamus by FDG-PET [24] and resting-state
fMRI [37]. Our results also showed increased metabol-
ism at the culmen of vermis in the cerebellum’s anterior
lobe, a region where abnormalities have been previously
reported in geriatric depression using MRI and voxel-
based morphometry [38]. Again we found increased me-
tabolism in the declive (posterior lobe in cerebellum),
which is involved in verbal working memory and has not
received much previous attention in depression [39]. We
found that the cluster size of reduced glucose metabol-
ism was higher than the cluster size of increased glucose
metabolism in MDD patients. One plausible way of inte-
grating these findings is that decreased metabolism in
insula, limbic system and basal ganglia is compensated
by an increased metabolism in the thalamus and cerebel-
lum [10].
Previously published meta-analyses in neuroimaging
studies on depression did not include Chinese patients
whereas our study also includes papers published in
Chinese therefore enlarging the overall sample consid-
ered. Stuhrmann et al [40] analyzed studies of fMRI on
emotional face processing in acutely depressed patients
compared with healthy controls. The abnormalities in
MDD patients showed mood-congruent processing bias
particularly in the amygdala, insula, parahippocampal
gyrus, fusiform face area, and putamen. Chen et al [15] also
used fMRI and found that depressed patients with bipolar
disorder had increased brain activity in caudate, precentral
gyrus and decreased inferior frontal gyrus. Fitzgerald et al
[8] used 3 different methods including fMRI, PET, and
SPECT while Sacher et al [10] and Delaveau et al [9] used
fMRI and PET.
Although there is a significant overlap between studies
already meta-analyzed by Fitzgerald et al. [8] and Sacher
et al. [10] and those here meta-analyzed [namely: Brody
et al. [24], Kennedy et al. [25], Kimbrell et al. [6] and
Saxena et al. [23], for a total of 102 patients and 94 controls
(196 subjects)], the authors here added more six studies,
encompassing more 87 patients and 75 controls (162 sub-
jects), for an increase of 82%. In addition, although in their
methodologies Sacher et al. and Delaveau et al. address
separately fMRI and PET studies, but their analyses were
carried out without distinguishing enough modalities. Rest
fMRI is also an important tool to detect brain metabolically
activity depend on blood oxygen level-dependent (BOLD)
signal which in very different from PET technology. The
diverse methods included could be a source of heterogen-
eity between studies in that we only include PET studies.
Stuhrmanm et al [40] only described the changed brain
region in their paper not using meta-analysis methods.
Our meta-analysis focuses on glucose metabolism PET
studies and included Chinese articles thus compiling a lar-
ger more homogeneous overall sample.
Although meta-analysis results across studies can help
us to identify consistent findings in the literature, they
may lack specificity as to the nature of any abnormality
described. Insula, limbic system, basal ganglia, thalamus,
and cerebellar activity changes are also found in other
mental illness [15,41-43]. Several limitations need to be
considered in the interpretation of our results. Firstly,
methodological differences in PET recording and mea-
surements may result in the heterogeneity among the
different studies [1] and the limitation of ALE meta-
analysis method [19]. However, ALE is widely accepted
method used in neuroimaging meta-analysis which could
correct for multiple comparisons and is different from
traditional meta-analysis. And samples of three studies
were geriatric depression and treatment-resistant depres-
sion patients. However, we only included FDG-PET
studies which should lead to a more homogenous sam-
ple. Secondly, publication bias affecting the primary
studies [44] could have influenced our results [45]. Last,
it should be noted that our results may be limited by a
small number of brain metabolism studies, the ALE
technique is very dependent on the number of foci in-
cluded in the analysis [46]. However, we found signifi-
cant ALE clusters that were consistent with the path
physiology of MDD.
Conclusion
In conclusion, our meta-analysis involving brain metabol-
ism PET studies in MDD patients showed dysfunctional
regions including insula, limbic system, basal ganglia, thal-
amus, and cerebellum that has been previously proposed
in depression. In particular, decreased insula activity might
play a key role in the neuropathology of depression, which
is compensated by increased metabolism in thalamus and
cerebellum. However, these results lack specificity as they
are similar to other neuropsychiatric diseases such as bi-
polar disorders and schizophrenia. Further research is re-
quired to find the specific brain regions which are the
primary physiological changes and which are the second-
ary changes involved in the neuropsychiatric network of
depression.
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